Successful technology transfer for production of drug candidate NlpD
The protein drug candidate NlpD, which is being developed by SelectImmune Pharma, needs adequate, large-scale production technology for continued development towards clinical trials. To achieve this goal, SelectImmune Pharma collaborates with the leading international manufacturer Lonza. The production technology has now successfully been transferred as a first step towards larger scale production.The NlpD protein was first identified in “nice bacteria”, which release the protein into human cells where it inhibits the basic protein production machinery, reducing inflammation and excessive